Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI – OncoDaily
Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI / cancer, Dana-Farber’s Breast Oncology Center, Durvalumab, inflammatory breast
Related Articles
User account | Research To Practice
Research To Practice requires users to log in to view educational content. All content is available without
Management of Stage III Non–Small Cell Lung Cancer – OncoDaily
Management of Stage III Non–Small Cell Lung Cancer / ASCO, cancer, Cleveland Clinic, Hematology, Jame Abraham, Lung cancer, MedOnc, Navneet Singh, non small
Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer
Abstract. Purpose: Breast cancer cells disseminate to distant sites via Tumor Microenvironment of Metastasis (TMEM) doorways. The TIE2 inhibitor rebastinib blocks TMEM doorway function in…
What Happens When US Hospitals Binge on Nurse Practitioners – Bloombe…
archived 24 Nov 2024 13:07:34 UTC
Antibody-drug Conjugates Lung Cancer | ADC Evolution
Discover ADCs for lung cancer, a new class of therapy created to attack tumor cells while reducing the toxicity on healthy cells.
How to avoid early mortality in acute promyelocytic leukemia
Abstract. Acute promyelocytic leukemia (APL), a phenotypically and genotypically unique subtype of acute myeloid leukemia, has seen unprecedented advances
Identification of defined molecular subgroups based on immunohistochemical analyses and potential therapeutic vulnerabilities of pulmonary carcinoids
Multi-omic studies have identified three molecular separated pulmonary carcinoid (PC) subgroups (A1, A2, B) with distinctive mRNA expression profiles (e.g. OTP/ASCL1/HNF1A). We aimed to establish…
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML
Key Points. SY-5609 repressed Myc, inhibited cell growth, induced lethality and depleted protein expressions in post-MPN sAML stem/progenitor cells.SY-5609
